ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
KaliVir Immunotherapeutics raised $14 million in a Series A extension funding round. The company secured the additional capital to advance its immunotherapy pipeline. The funding supports continued development of its therapeutic candidates.
Tap to vote and see what everyone thinks.
Summary by ByteBrief